StockNews.com initiated coverage on shares of Avinger (NASDAQ:AVGR – Get Free Report) in a research report issued on Wednesday. The brokerage set a “hold” rating on the medical device company’s stock.
Separately, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Avinger in a research report on Thursday, March 21st.
Get Our Latest Research Report on AVGR
Avinger Stock Performance
Avinger (NASDAQ:AVGR – Get Free Report) last issued its quarterly earnings results on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by ($4.57). The firm had revenue of $1.91 million during the quarter, compared to the consensus estimate of $2.52 million. As a group, research analysts forecast that Avinger will post -2.08 EPS for the current fiscal year.
Avinger Company Profile
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
Read More
- Five stocks we like better than Avinger
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Charles Schwab Fortifies its Uptrend on EPS Beat
- What Are Growth Stocks and Investing in Them
- Lockheed Martin Stock Aims for a Fresh All-Time High
- Investing in large cap stocks: Diving into big caps
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.